VNDA (Vanda Pharma) רווח נקי למניה אחת בשנים עשר החודשים האחרונים

The chart-confirmed market EPS (TTM) for Vanda Pharmaceuticals (VNDA) stands at -221.70. The business maintains a stable share in a niche neuropsychology segment, avoiding pricing pressure due to product uniqueness. Strict FDA oversight and the ownership of exclusive rights to Fanapt and Hetlioz block new entrants. Furthermore, Vanda Pharmaceuticals (VNDA) is developing innovative treatments for skin pathologies and sleep disorders through academic alliances.
פילוחי מדדים פיננסיים ומדדי שוק עבור Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals revenues are critically dependent on patent protection and insurance reimbursements for antipsychotic medications. Year-over-year EPS (TTM) growth measures the dynamics of rolling net income per share, accounting for currency adjustments. The current value of -221.70 helps investors assess the sustainability of business expansion and avoid entering the asset at the peak of the cycle. By analyzing the rolling year-over-year EPS chart, one can timely identify the issuer's fundamental strength.